Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01728103 · ClinicalTrials.gov registry record
Prospective Collection of Female Specimens for Testing With Gen-Probe APTIMA (Registered Trademark) Assays
A clinical trial, sponsored by Gen-Probe, Incorporated.
- Terminated
- Registry status
- 1,336
- Enrollment target
NCT01728103: Clinical Trial study, sponsored by Gen-Probe, Incorporated.
NCT01728103 is a clinical trial that was terminated before completion, run by Gen-Probe, Incorporated. The registered enrollment target is 1,336 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01728103 was terminated before completion, sponsored by Gen-Probe, Incorporated.
- TERMINATED
- Registry status
- 1,336 participants
- Enrollment target
Study Summary
The objective of this study is to obtain female first-catch urine, vaginal, cervical and endocervical swabs for testing with multiple APTIMA Assays on the Gen-Probe PANTHER® and TIGRIS® Systems.
Interventions
- DEVICE APTIMA® Trichomonas vaginalis & APTIMA® COMBO 2® Assays
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,336 participants |
| Start Date | 2013-01 |
Why NCT01728103 stopped before completion
NCT01728103 is an observational study that tracks outcomes without assigning an intervention. Its 1,336 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which APTIMA® Trichomonas vaginalis & APTIMA® COMBO 2® Assays is the first listed.
NCT01728103 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01728103 about?
NCT01728103 is a clinical study titled "Prospective Collection of Female Specimens for Testing With Gen-Probe APTIMA (Registered Trademark) Assays". The objective of this study is to obtain female first-catch urine, vaginal, cervical and endocervical swabs for testing with multiple APTIMA Assays on the Gen-Probe PANTHER® and TIGRIS® Systems.
What is the current status of trial NCT01728103?
This trial is currently terminated. The enrollment target is 1,336 participants. The study started on 2013-01.
What interventions are being tested in trial NCT01728103?
The interventions under investigation include: APTIMA® Trichomonas vaginalis & APTIMA® COMBO 2® Assays (DEVICE).
Who is sponsoring clinical trial NCT01728103?
This trial is sponsored by Gen-Probe, Incorporated, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06972056 · 1,335 participants · Phase 4
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- NCT05415761 · 1,332 participants · NA
Comparative Effectiveness of Mobile Health Smoking Cessation Approaches Among Underserved Patients in Primary Care
- NCT05511298 · 1,332 participants
Empowering Students Project
- NCT06934876 · 1,332 participants
Waveform Capnography Compared to Colorimetric Carbon Dioxide Detection During Tracheal Intubation of Critically Ill Adults
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia